 This is a prospective, randomized, double-blind, sham-controlled, multicenter, Phase 3 study of OTO-201 administered intraoperatively in pediatric subjects with bilateral middle ear effusion requiring TT tympanostomy tube placement. One dose level 6 mg of OTO-201 was evaluated relative to sham empty syringe. 